30 closest matches · ranked by relevance
Methamphetamine Dependence · Methamphetamine Withdrawal
Primary: Methamphetamine Selective Severity Assessment (MSSA) — 48.2 "units on a scale" — p=<0.05
Methamphetamine Use Disorder
Primary: Number of Participants With Treatment Response During Medication Phase at Stage 1 — 10; 18; 284; 91 Participants
Methamphetamine Use Disorder
Primary: Participants Categorized as "Responders" — 11 Participants
Methamphetamine Use Disorder
Primary: Reinforcing Effects of Methamphetamine Following Methylphenidate (0 mg; Placebo) Maintenance. — 0; 0; 3.33; 7.25 Trials Completed
Methamphetamine Use Disorder
Primary: Estimate the Treatment Effect of Bupropion for Methamphetamine (Meth) Dependence. — 5.6; 6.0 days
Methamphetamine Dependence
Primary: Measure of Methamphetamine Withdrawal — 3.7283; 10.056 units on a scale
Methamphetamine Dependence
Primary: Percentage of Participants With Methamphetamine-positive Urine Drug Screens — 85; 65 Percentage of participants
Methamphetamine Dependence · Methamphetamine Abuse
Primary: Number of Methamphetamine Doses Self-Administered — 1.25; 0; 6.13; 4 Number of Methamphetamine Doses
Stimulant Dependence · Methamphetamine-dependence · Addiction, Drug
Primary: Retention in the Study — 28.2; 45.4 Days — p=0.1760
Methamphetamine Dependence
Primary: Side Effects Checklist — 9.6515 units on a scale — p=0.05
Methamphetamine
Primary: Abstinence (Weeks 6 - 12) — 49; 49; 43; 48 Participants
Substance Abuse · HIV Infections
Primary: To Test the Hypothesis That Aripiprazole 20 mg Daily Will Reduce Methamphetamine Use Significantly More Than Placebo Among Methamphetamine-dependent Individuals. — 44…
Depression · Dual Diagnosis · Drug Addiction
Primary: Hamilton Depression Rating Scale (HAMD) Scores — 16.76; 17.65; 1.67; 16.24 score on a scale
HIV-1-infection · Methamphetamine-dependence
Primary: HIV Transcription (Cell-associated HIV RNA) in Peripheral Blood — 10.45; 57.38 copies/million cells
Cocaine Use Disorder · Methamphetamine Abuse · Cocaine Dependence
Primary: Percentage of Participants Who Receive at Least 20 Sessions of rTMS/Sham Over the Treatment Period. — 29; 40; 37; 23 Participants
Methamphetamine Dependence
Primary: Number of Subjects Showing Abstinence — 14; 20 Participants
Methamphetamine Dependence · Substance Abuse · Methamphetamine Abuse
Primary: End of Treatment Abstinence — 5; 4 Participants
Substance Abuse · HIV Infections
Primary: Change in Number of Positive Methamphetamine Urine Tests, Comparing Baseline (Week 0) to Final Visit (Week 12). — 40; 6 Percentage reduction
Methamphetamine Dependence · Substance Abuse · Methamphetamine Abuse
Primary: Change in MA Positive Urine Drug Screens Among Participants Randomly Assigned to Receive Varenicline Versus Placebo. — 7.4; 2.3 total MA-free urine drug screens
Methamphetamine Dependence
Primary: Heart Rate — 79.66 beats per minute
Methamphetamine-dependence
Primary: Functional Connectivity During Resting State Magnetic Resonance Imaging (MRI) — 0.91; 0.52; 0.54; 0.32 Fisher's Z-score
Methamphetamine Dependence
Primary: Time Till Relapse — 7; -8 Days to Relapse — p=<0.05
Methamphetamine Dependence
Primary: Clean Urine Drug Screen — 13.1; 12.7 Clean urine drug screens
Methamphetamine Addiction · Crystal Meth Addiction · Amphetamine Addiction
Primary: Systolic Blood Pressure — 126.4; 127.4 mm Hg
Substance Abuse · HIV Infections
Primary: Feasibility: Proportion of Persons Screened Who Are Eligible and Enrolled — 30 Eligible persons screened who enrolled
Methamphetamine Dependence, Treatment Seeking
Primary: Methamphetamine Abstinence
Continuous Methamphetamine Abuse
Primary: Self-report Effects of High. — 0; 0; 0; 0 units on a scale
Methamphetamine · Amphetamine Dependence · Pharmacogenetics
Primary: Treatment Effectiveness Score — 16.1; 10.6 urine drug screens
Methamphetamine Dependence · HIV Infection
Primary: Methamphetamine Use — 9; 10 Participants
Methamphetamine Abuse · Opioid-use Disorder · HIV Seropositivity
Primary: Increase in HIV Viral Suppression for HIV-positive Participants: High- vs. Low-Intensity Frontline Intervention With SMS in Stage 2 — 31; 35; 6; 3 Participants — p=0.447